Microsoft co-founder Bill Gates spoke with CNBC’s Andrew Ross Sorkin about the coronavirus vaccine and treatment study results thus far and which efforts out there he thinks show the most promise.

On the paradigm shift to remote work Gates believes that there would be “less long-distance travel” and “more flexibility about jobs.” in the aftermath of the pandemic.

Bill Gates: Covid-19 testing is a ‘waste’ unless results are available within 48 hours

Source: CBS Squawk Box

Reprinted for educational purposes and social benefit, not for profit. 

Billionaire philanthropist Bill Gates said therapeutic drugs to treat the coronavirus could reduce the death rate substantially this year but a vaccine will be crucial to bringing back a sense of normalcy to the society. “You can see the therapeutic benefit faster than the protective benefit,” Gates said in an interview that aired Tuesday on CNBC’s “Squawk Box.” “So I think there’s a good chance we’ll have substantial death-rate reduction by the end of the year with the combination of those new tools.” The Microsoft co-founder and co-chair of the Bill and Melinda Gates Foundation said remdesivir was one of the leading treatments in the therapeutic research. Remdesivir is an antiviral drug from Gilead Sciences that has shown to have reduced the risk of death for severely sick Covid-19 patients by 62% compared with standard care alone. Gates said there are two other antivirals that scientists are looking into, which can be administered orally instead of being injected with an IV like the remdesivir treatment. The Bill and Melinda Gates Foundation announced plans in February to donate $100 million to vaccine research and treatment efforts for the coronavirus as part of the World Health Organization’s request for $675 million in contributions to fight the spread of the virus. In June, the foundation pledged an additional $1.6 billion to the Gavi vaccine alliance, an organization focused on efforts to immunize children amid the coronavirus pandemic. “Also I’d say monoclonal antibodies are probably the most promising class. …You have people like Regeneron, Eli Lilly and AstraZeneca doing some pretty strong work,” Gates told Andrew Ross Sorkin in the in Monday’s interview. Even though these new therapeutics will significantly help coronavirus patients suffering from severe symptoms, he said it won’t “drive us back to complete normalcy.” “Until you really block transmission, have long periods of time without anybody going in the hospital, the concern is going to be there,” he said. Several pharmaceutical companies have been testing their potential vaccines in clinical trials with some entering late-stage human trials in a race to win regulatory approval before the end of 2020. U.S. drugmaker Pfizer and German biotech company BioNTech announced Monday that they just began their late-stage human trial. Earlier this month, they said one of their four vaccine candidates produced neutralizing antibodies, which researchers believe is necessary to build immunity to the virus, in all participants who received two of the 10 or 30 microgram doses. Last week, Pfizer and BioNTech received $1.95 billion in funding from the U.S. government to produce and deliver 100 million doses of their vaccine if it proves safe and effective.